Latest KFF Health News Stories
Daylight On Diabetes Drugs: Nevada Bill Would Track Insulin Makers’ Profits
With the cost of medications up 300 percent in the past decade, supporters see this as a first step to rein in prices.
When An Insurer Balks And Treatment Stops
A 22-year old man from Orange County, Calif., alleges in a lawsuit that his health insurer stopped paying for a crucial — and expensive — immunotherapy drug, leading him to become seriously ill. Treatments for patients with similar conditions are increasingly denied or interrupted, experts and patient advocates say.
Drug Rebates Reward Industry Players — And Often Hurt Patients
A new JAMA study examines how drug rebates can direct money to middlemen and force Medicare patients to cough up more money.
New York State Wants Its Prescription Drug Money Back — Or Else
A new law gives Medicaid regulators power to threaten drugmakers with cost-effectiveness scrutiny unless they grant additional rebates.
Populares antiácidos, ¿podrían causar daño a los riñones?
Una nueva investigación ha vinculado a los PPI, con graves efectos secundarios, incluyendo enfermedad renal crónica, y demandas presentadas recientemente alegan que los que producen la droga deberían haber sabido sobre sus daños potenciales.
Do Best-Selling Drugs That Calm Stomachs Damage Kidneys? The Answer’s Unclear.
With flawed systems for tracking the side effects of prescription drugs, a link between proton pump inhibitors and kidney disease suggested by research cannot be proven. Patients who swear by the drugs hope it won’t be.
Overwrought Marketing? Ads, Not Research, Create Some Pharma Best-Sellers
A look at how and why strategic, star-studded advertising brought a drug for a little-known neurological condition into your home.
Nearly 1 In 3 Recent FDA Drug Approvals Followed By Major Safety Actions
More than 70 drugs approved from 2001 through 2010 ran into safety concerns later that resulted in withdrawals from the market, “black box” warnings or other actions.
Cómo aliviar el dolor financiero de los planes de salud con deducibles altos
Pase lo que pase con el Obamacare, es bastante seguro que una tendencia en la atención de salud continuará: cada vez más personas tendrán planes de salud con deducibles altos. Cómo enfrentarlos.
How To Ease The Financial Pain Of High-Deductible Health Plans
You might save money on premiums with a high-deductible health plan only to find you’re spending more on the back end. These tips will help you minimize your expenses for medical treatment and prescriptions.
Negotiating Drug Prices: Should State Agencies Band Together?
A California lawmaker wants to strengthen collaboration among public agencies to bring down costs to taxpayers.
With Drug Costs In Crosshairs, Health Firms Gave Generously To Trump’s Inauguration
Led by Pfizer and Amgen, about 10 health care firms contributed to President Donald Trump’s inauguration, which earned them entry into private events with the president and vice president.
Nonprofit Linked To PhRMA Rolls Out Campaign To Block Drug Imports
The advocacy group behind an expensive media blitz opposing Canadian drug imports has deep ties to the drug industry’s largest trade group.
California Presses Forward In Fight To Regulate Pharma
Such efforts have previously failed in the face of opposition from the drug industry, which questions their effectiveness and contends prices reflect research and development costs.
¿Siente dolor? Muchos médicos dicen que los analgésicos no son la solución
Muchos médicos ya no recetan generosamente analgésicos opioides como la oxicodona o el fentanilo para el dolor de espalda o las migrañas. En cambio, recurren cada vez más a opciones no farmacológicas como la acupuntura y la fisioterapia.
In Pain? Many Doctors Say Opioids Are Not The Answer
The opioid addiction crisis has led to a crackdown on prescriptions for chronic pain patients, who are increasingly given less addictive painkillers along with referrals for acupuncture, physical therapy, massage and even yoga.
GAO To Launch Investigation Of FDA’s Orphan Drug Program
The Government Accountability Office said it will investigate potential abuses of the orphan drug program, which offers incentives to drugmakers to develop medicines for rare diseases.
Prescription Drug Costs Are On The Rise; So Are The TV Ads Promoting Them
Spending on consumer advertising by drugmakers has increased 62 percent since 2012.
$89,000 Orphan Drug Gets A New Owner — And Likely A New Price
Marathon, maker of an expensive treatment for Duchenne muscular dystrophy, sells the drug for $140 million in cash and stock to PTC Therapeutics.
Sticker Shock Forces Thousands Of Cancer Patients To Skip Drugs, Skimp On Treatment
A growing number of patients fail to fill prescriptions because the cost of cancer drugs is too high.
